The Spanish Competition Authority clears a dual pricing system (Pfizer / Cofares)

On 19 January 2017 the Spanish Competition Authority (SCA) issued a decision clearing PFIZER of antitrust charges and blessing PFIZER’s dual pricing system (SCA Decision). In 2009, the SCA decided (First Decision) to close the antitrust investigation against COMPAÑÍA FARMACÉUTICA ESPAÑOLA, S.A. (COFARES), a wholesale distributor, and PFIZER. The investigation started following a complaint filed by SPAIN PHARMA, S.A. (SPAIN PHARMA) reporting the existence of an agreement by means of which PFIZER prevented COFARES from exporting PFIZER’s pharmaceutical specialties to other EU States and established a dual-pricing system on the basis of geographic destination of the pharmaceuticals. The First Decision was challenged by SPAIN PHARMA before the Appeal Court (AC). The AC partially upheld the

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.


Version PDF


  • Callol, Coca & Asociados (Madrid)


Pedro Callol, The Spanish Competition Authority clears a dual pricing system (Pfizer / Cofares), 19 janvier 2017, e-Competitions January 2017, Art. N° 83837

Visites 509

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues